Table 3 Multivariate analysis comparing ctDNA-high, high-risk PET, BN2/EZB/ST2 clusters, IPI and COO in terms of PFS.

From: Integration of [18F]FDG-PET radiomics with liquid biopsy improves outcome prediction in newly diagnosed diffuse large B-cell lymphoma

Variable

p

HR

95% CI

ctDNA-high

0.012

2.46

1.22–4.96

High-risk PET

<0.001

6.55

2.38–18.03

BN2/EZB/ST2

0.020

0.33

0.13–0.84

IPI ≥ 3

0.662

0.85

0.41–1.76

COO (non-GC)

0.259

1.58

0.71–3.47

Back to article page